Evidence map›Paper›PMID 34610982›Full record

Observational studyDiabetes2021

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.

Sharmaine Thirunavukarasu, Nicholas Jex, Amrit Chowdhary, Imtiaz Ul Hassan, Sam Straw, Thomas P Craven, Miroslawa Gorecka, David Broadbent, Peter Swoboda, Klaus K Witte and 6 more

2 registry-linked trialsOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06784154 recruitingnot on this mapstarted 2024, after this paper: background citation

The Association of Ectopic Fat and Cardiovascular Disease in People Living With HIV and General Populations: A Cross Sectional Analysis

TypeobservationalSponsorUniversity of LiverpoolRan2024 to 2027Enrolled100ConditionsCardiometabolic Syndrome, HivArmsNon-interventional
NCT07070765 narecruitingnot on this mapstarted 2025, after this paper: background citation

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity - SPRINT

TypeinterventionalSponsorUniversity of AberdeenRan2025 to 2028Enrolled70ConditionsBreast CancerArmsSodium-glucose transport-2 (SGLT-2) inhibitors, Standard medical treatment
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Phosphorus Magnetic Resonance Spectroscopy (Medicina (Kaunas, Lithuania) · 2023
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. [Diabetic cardiomyopathy: a focus on sodium-glucose cotransporter type 2 inhibitors].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Sharmaine ThirunavukarasuMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.ORCID 0000-0003-2535-8407
Nicholas JexMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Amrit ChowdharyMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Imtiaz Ul HassanMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Sam StrawDivision of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Thomas P CravenMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Miroslawa GoreckaMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
David BroadbentDepartment of Medical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds, U.K.
Peter SwobodaMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Klaus K WitteDivision of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Richard M CubbonDivision of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Hui XueNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Peter KellmanNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
John P GreenwoodMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Sven PleinMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K.
Eylem LeveltMultidisciplinary Cardiovascular Research Centre and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, U.K. e.levelt@leeds.ac.uk.ORCID 0000-0002-3799-7102
University of Leeds · GBNational Institutes of Health · USLeeds Teaching Hospitals NHS Trust · GB

Funding

British Heart Foundation FS/12/80/29821British Heart Foundation FS/CRTF/20/24003British Heart Foundation FS/CRTF/20/24071British Heart Foundation RG/16/1/32092Wellcome TrustWellcome Trust 221690/Z/20/Z
6 · The paper itself

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and

Indexed as

AgedBenzhydryl CompoundsCell SizeCohort StudiesDiabetes Mellitus, Type 2Diabetic CardiomyopathiesEnergy MetabolismFemaleGlucosidesHeartHumansLongitudinal StudiesMaleMiddle AgedMyocardiumMyocytes, CardiacBenzhydryl CompoundsempagliflozinGlucosides

Identifiers

PMID34610982
PMCPMC8660983
OpenAlexW3203350643

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.